LEADS BIOLABS-B(09887): Six study abstracts to be presented at ESMO 2026

LEADS BIOLABS-B(09887) announced that the full abstracts of six studies (covering clinical research, translational research, and meta-analysis) on its self-developed Vilixin (opamtisumumab, an anti-PD-L1/41BB bispecific antibody) and LBL-034 (a GPRC5D/CD3 bispecific T-cell engager, TCE) have been published on the official website of the 2026 European Society for Medical Oncology Annual Meeting (2026 ESMO). These data collectively demonstrate the trend of durable responses and long-tail survival benefits of Vilixin across multiple immune "cold tumors," supporting its potential as a pan-tumor therapy and highlighting the differentiated capabilities of the company's X-body and TCE technology platforms. Notably, three studies of Vilixin and LBL-034 were selected for preferred oral presentations at 2026 ESMO, with one study selected as a Late-Breaking Abstract (LBA). Detailed and updated data from these studies will be released during the oral presentation sessions at 2026 ESMO.